Signaturefd, LLC Esperion Therapeutics, Inc. Transaction History

Signaturefd, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 29, 2024	BUY	$1.84 - $3.24 $629 - $1,108	342 New	342 $0
Q1 2023 Apr 28, 2023	SELL	$1.46 - $7.3 $2,505 - $12,526	-1,716 Reduced 59.48%	1,169 $1,000
Q4 2022 Jan 27, 2023	SELL	$5.09 - $8.5 $2,102 - $3,510	-413 Reduced 12.52%	2,885 $17,000
Q3 2022 Nov 08, 2022	BUY	$5.45 - $8.13 $2,196 - $3,276	403 Added 13.92%	3,298 $22,000
Q2 2022 Aug 10, 2022	BUY	$4.77 - $6.67 $12,010 - $16,795	2,518 Added 667.9%	2,895 $18,000
Q1 2022 May 02, 2022	SELL	$3.34 - $5.56 $1,693 - $2,818	-507 Reduced 57.35%	377 $2,000
Q4 2021 Jan 25, 2022	BUY	$4.81 - $11.92 $3,790 - $9,392	788 Added 820.83%	884 $4,000
Q3 2021 Oct 28, 2021	BUY	$11.34 - $21.37 $1,088 - $2,051	96 New	96 $1,000
Q3 2020 Nov 03, 2020	SELL	$31.18 - $52.71 $592 - $1,001	-19 Closed	0 $0
Q2 2020 Jul 30, 2020	BUY	$30.04 - $51.31 $570 - $974	19 New	19 $1,000
Q1 2019 May 09, 2019	SELL	$40.11 - $53.57 $40 - $53	-1 Closed	0 $0
Q4 2018 Feb 13, 2019	BUY	$36.99 - $59.11 $36 - $59	1 New	1 $0

210

129M

1.67M

930K

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $119M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

Get notified when there are updates to the investment portfolio of Signaturefd, LLC, based on Form 13F filings with the SEC.

Stay updated on Signaturefd, LLC with notifications on news.